Download PDF
Aktuelle Neurologie 2009; 36(1): 19-29
DOI: 10.1055/s-0028-1090129
Übersicht

© Georg Thieme Verlag KG Stuttgart · New York

Neurokognitive Effekte häufig in der Epilepsiebehandlung eingesetzter Antiepileptika

Neurocognitive Effects of Antiepileptic Drugs Frequently Used in Long-Term Treatment of Epilepsies: A ReviewI.  Oppenheim1 , B.  Brunner1 , A.  Pöpel1 , G.  Krämer1 , H.  Jokeit1
  • 1Schweizerisches Epilepsie-Zentrum, Zürich
Further Information

Publication History

Publication Date:
16 January 2009 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Antiepileptika (AED) verändern, basierend auf sehr unterschiedlichen Mechanismen, die Erregbarkeit von Nervenzellen und können so auch neurokognitive Prozesse beeinflussen. In den vergangenen Jahren wurden mehrere neue Antiepileptika zugelassen, die neben der Epilepsie auch zur Behandlung des neuropathischen Schmerzes und zur Stimmungsstabilisierung in der Psychiatrie eingesetzt werden. Es gibt jedoch nur wenige methodisch hinreichend kontrollierte Studien, die die neurokognitiven Wirkungen von Antiepileptika untersucht haben. Weiterhin fehlen Untersuchungen zu kognitiven Wirkungen neuer Antiepileptika in Kombinationstherapie mit älteren und anderen neuen Antiepileptika. Die Mehrzahl der neueren AED (Gabapentin, Lamotrigin, Levetiracetam, Oxcarbazepin) weisen gegenüber den älteren ein günstigeres neurokognitives Profil auf. Unter den neueren AED besteht bei Topiramat das höchste Risiko für kognitive Störwirkungen, die aber reversibel sind. Die Datenlage für Zonisamid ist für eine abschließende Beurteilung noch unzureichend, aber es verdichten sich Hinweise darauf, dass es häufiger kognitive Störwirkungen induziert als Gabapentin, Levetiracetam und Lamotrigin.

Abstracts

Antiepileptic drugs (AED) alter neuronal excitation levels and may lead to neurocognitive changes. In recent years, several new AEDs have been introduced which are additionally used to treat mood disorders, neuropathic pain and migraine. Generally, very few controlled trials have systematically examined the cognitive side effects of AEDs. In particular, polytherapy with the newer AEDs is under-investigated. In this paper we review the most relevant data pertaining to neurocognitive side effects of AEDs that are currently prescribed in Switzerland for the long-term treatment of epilepsies.

Schlüsselwörter

Antiepileptika - Nebenwirkungen - Kognition - Neuropsychologie - Epilepsie

Key words

antiepileptic drugs - side effects - cognition - neuropsychology - epilepsy

Literatur

  • 1 Marques C M, Caboclo L O, da Silva T I. et al . Cognitive decline in temporal lobe epilepsy due to unilateral hippocampal sclerosis.  Epilepsy Behav. 2007;  10 477-485
    CrossrefPubMedGoogle Scholar
  • 2 Jokeit H, Schacher M. Neuropsychological aspects of type of epilepsy and etiological factors in adults.  Epilepsy Behav. 2004;  5 (Suppl. 1) S14-20
    CrossrefPubMedGoogle Scholar
  • 3 Landmark C J. Targets for antiepileptic drugs in the synapse.  Med Sci Monit. 2007;  13 RA1-7
    PubMedGoogle Scholar
  • 4 Hessen E, Lossius M I, Reinvang I. et al . Influence of major antiepileptic drugs on attention, reaction time, and speed of information processing: results from a randomized, double-blind, placebo-controlled withdrawal study of seizure-free epilepsy patients receiving monotherapy.  Epilepsia. 2006;  47 2038-2045
    CrossrefPubMedGoogle Scholar
  • 5 Gallassi R, Morreale A, Di Sarro R. et al . Cognitive effects of antiepileptic drug discontinuation.  Epilepsia. 1992;  33 (Suppl. 6) S41-44
    PubMedGoogle Scholar
  • 6 Chen Y, Chi Chow J, Lee I. Comparison the cognitive effect of anti-epileptic drugs in seizure-free children with epilepsy before and after drug withdrawal.  Epilepsy Res. 2001;  44 65-70
    CrossrefPubMedGoogle Scholar
  • 7 Martin R, Meador K, Turrentine L. et al . Comparative cognitive effects of carbamazepine and gabapentin in healthy senior adults.  Epilepsia. 2001;  42 764-771
    CrossrefPubMedGoogle Scholar
  • 8 Meador K J, Loring D W, Ray P G. et al . Differential cognitive effects of carbamazepine and gabapentin.  Epilepsia. 1999;  40 1279-1285
    CrossrefPubMedGoogle Scholar
  • 9 Meador K J, Loring D W, Ray P G. et al . Differential cognitive and behavioral effects of carbamazepine and lamotrigine.  Neurology. 2001;  56 1177-1182
    PubMedGoogle Scholar
  • 10 Gillham R A, Williams N, Wiedmann K D. et al . Cognitive function in adult epileptic patients established on anticonvulsant monotherapy.  Epilepsy Res. 1990;  7 219-225
    CrossrefPubMedGoogle Scholar
  • 11 Kang H C, Eun B L, Wu Lee C. et al . The effects on cognitive function and behavioral problems of topiramate compared to carbamazepine as monotherapy for children with benign rolandic epilepsy.  Epilepsia. 2007;  48 1716-1723
    CrossrefPubMedGoogle Scholar
  • 12 Aikia M, Jutila L, Salmenpera T. et al . Comparison of the cognitive effects of tiagabine and carbamazepine as monotherapy in newly diagnosed adult patients with partial epilepsy: pooled analysis of two long-term, randomized, follow-up studies.  Epilepsia. 2006;  47 1121-1127
    CrossrefPubMedGoogle Scholar
  • 13 Dodrill C B, Arnett J L, Deaton R. et al . Tiagabine versus phenytoin and carbamazepine as add-on therapies: effects on abilities, adjustment, and mood.  Epilepsy Res. 2000;  42 123-132
    CrossrefPubMedGoogle Scholar
  • 14 Read C L, Stephen L J, Stolarek I H. et al . Cognitive effects of anticonvulsant monotherapy in elderly patients: a placebo-controlled study.  Seizure. 1998;  7 159-162
    PubMedGoogle Scholar
  • 15 Kelly K M. Gabapentin. Antiepileptic mechanism of action.  Neuropsychobiology. 1998;  38 139-144
    CrossrefPubMedGoogle Scholar
  • 16 Dodrill C B, Arnett J L, Hayes A G. et al . Cognitive abilities and adjustment with gabapentin: results of a multisite study.  Epilepsy Res. 1999;  35 109-121
    CrossrefPubMedGoogle Scholar
  • 17 Salinsky M C, Binder L M, Oken B S. et al . Effects of gabapentin and carbamazepine on the EEG and cognition in healthy volunteers.  Epilepsia. 2002;  43 482-490
    CrossrefPubMedGoogle Scholar
  • 18 Salinsky M C, Storzbach D, Spencer D C. et al . Effects of topiramate and gabapentin on cognitive abilities in healthy volunteers.  Neurology. 2005;  64 792-798
    PubMedGoogle Scholar
  • 19 Mortimore C, Trimble M, Emmers E. Effects of gabapentin on cognition and quality of life in patients with epilepsy.  Seizure. 1998;  7 359-364
    CrossrefPubMedGoogle Scholar
  • 20 Leach J P, Girvan J, Paul A. et al . Gabapentin and cognition: a double blind, dose ranging, placebo controlled study in refractory epilepsy.  J Neurol Neurosurg Psychiatry. 1997;  62 372-376
    CrossrefPubMedGoogle Scholar
  • 21 Hurley S C. Lamotrigine update and its use in mood disorders.  Ann Pharmacother. 2002;  36 860-873
    CrossrefPubMedGoogle Scholar
  • 22 Smith D, Baker G, Davies G. et al . Outcomes of add-on treatment with lamotrigine in partial epilepsy.  Epilepsia. 1993;  34 312-322
    CrossrefPubMedGoogle Scholar
  • 23 Pressler R M, Binnie C D, Coleshill S G. et al . Effect of lamotrigine on cognition in children with epilepsy.  Neurology. 2006;  66 1495-1499
    CrossrefPubMedGoogle Scholar
  • 24 Zoccali R, Muscatello M R, Bruno A. et al . The effect of lamotrigine augmentation of clozapine in a sample of treatment-resistant schizophrenic patients: a double-blind, placebo-controlled study.  Schizophr Res. 2007;  93 109-116
    CrossrefPubMedGoogle Scholar
  • 25 Placidi F, Marciani M G, Diomedi M. et al . Effects of lamotrigine on nocturnal sleep, daytime somnolence and cognitive functions in focal epilepsy.  Acta Neurol Scand. 2000;  102 81-86
    CrossrefPubMedGoogle Scholar
  • 26 Aldenkamp A P, Arends J, Bootsma H P. et al . Randomized double-blind parallel-group study comparing cognitive effects of a low-dose lamotrigine with valproate and placebo in healthy volunteers.  Epilepsia. 2002;  43 19-26
    PubMedGoogle Scholar
  • 27 Meador K J, Loring D W, Vahle V J. et al . Cognitive and behavioral effects of lamotrigine and topiramate in healthy volunteers.  Neurology. 2005;  64 2108-2114
    CrossrefPubMedGoogle Scholar
  • 28 Werz M A, Schoenberg M R, Meador K J. et al . Subjective preference for lamotrigine or topiramate in healthy volunteers: relationship to cognitive and behavioral functioning.  Epilepsy Behav. 2006;  8 181-191
    CrossrefPubMedGoogle Scholar
  • 29 Smith M E, Gevins A, McEvoy L K. et al . Distinct cognitive neurophysiologic profiles for lamotrigine and topiramate.  Epilepsia. 2006;  47 695-703
    CrossrefPubMedGoogle Scholar
  • 30 Blum D, Meador K, Biton V. et al . Cognitive effects of lamotrigine compared with topiramate in patients with epilepsy.  Neurology. 2006;  67 400-406
    CrossrefPubMedGoogle Scholar
  • 31 Zhou B, Zhang Q, Tian L. et al . Effects of levetiracetam as an add-on therapy on cognitive function and quality of life in patients with refractory partial seizures.  Epilepsy Behav. 2008;  12 305-310
    CrossrefPubMedGoogle Scholar
  • 32 Ciesielski A S, Samson S, Steinhoff B J. Neuropsychological and psychiatric impact of add-on titration of pregabalin versus levetiracetam: a comparative short-term study.  Epilepsy Behav. 2006;  9 424-431
    CrossrefPubMedGoogle Scholar
  • 33 Gomer B, Wagner K, Frings L. et al . The influence of antiepileptic drugs on cognition: a comparison of levetiracetam with topiramate.  Epilepsy Behav. 2007;  10 486-494
    CrossrefPubMedGoogle Scholar
  • 34 Neyens L G, Alpherts W C, Aldenkamp A P. Cognitive effects of a new pyrrolidine derivative (levetiracetam) in patients with epilepsy.  Prog Neuropsychopharmacol Biol Psychiatry. 1995;  19 411-419
    CrossrefPubMedGoogle Scholar
  • 35 Meador K J, Gevins A, Loring D W. et al . Neuropsychological and neurophysiologic effects of carbamazepine and levetiracetam.  Neurology. 2007;  69 2076-2084
    CrossrefPubMedGoogle Scholar
  • 36 Mecarelli O, Vicenzini E, Pulitano P. et al . Clinical, cognitive, and neurophysiologic correlates of short-term treatment with carbamazepine, oxcarbazepine, and levetiracetam in healthy volunteers.  Ann Pharmacother. 2004;  38 1816-1822
    CrossrefPubMedGoogle Scholar
  • 37 Vajda F J. New antiepileptic drugs.  J Clin Neurosci. 2000;  7 88-101
    CrossrefPubMedGoogle Scholar
  • 38 Tzitiridou M, Panou T, Ramantani G. et al . Oxcarbazepine monotherapy in benign childhood epilepsy with centrotemporal spikes: a clinical and cognitive evaluation.  Epilepsy Behav. 2005;  7 458-467
    CrossrefPubMedGoogle Scholar
  • 39 Donati F, Gobbi G, Campistol J. et al . The cognitive effects of oxcarbazepine versus carbamazepine or valproate in newly diagnosed children with partial seizures.  Seizure. 2007;  16 670-679
    CrossrefPubMedGoogle Scholar
  • 40 Salinsky M C, Spencer D C, Oken B S. et al . Effects of oxcarbazepine and phenytoin on the EEG and cognition in healthy volunteers.  Epilepsy Behav. 2004;  5 894-902
    CrossrefPubMedGoogle Scholar
  • 41 Aikia M, Kalviainen R, Sivenius J. et al . Cognitive effects of oxcarbazepine and phenytoin monotherapy in newly diagnosed epilepsy: one year follow-up.  Epilepsy Res. 1992;  11 199-203
    CrossrefPubMedGoogle Scholar
  • 42 Twyman R E, Rogers C J, Macdonald R L. Differential regulation of gamma-aminobutyric acid receptor channels by diazepam and phenobarbital.  Ann Neurol. 1989;  25 213-220
    CrossrefPubMedGoogle Scholar
  • 43 Riva D, Devoti M. Discontinuation of phenobarbital in children: effects on neurocognitive behavior.  Pediatr Neurol. 1996;  14 36-40
    CrossrefPubMedGoogle Scholar
  • 44 Tonekaboni S H, Beyraghi N, Tahbaz H S. et al . Neurocognitive effects of phenobarbital discontinuation in epileptic children.  Epilepsy Behav. 2006;  8 145-148
    CrossrefPubMedGoogle Scholar
  • 45 Meador K J, Loring D W, Moore E E. et al . Comparative cognitive effects of phenobarbital, phenytoin, and valproate in healthy adults.  Neurology. 1995;  45 1494-1499
    CrossrefPubMedGoogle Scholar
  • 46 Chen Y J, Kang W M, So W C. Comparison of antiepileptic drugs on cognitive function in newly diagnosed epileptic children: a psychometric and neurophysiological study.  Epilepsia. 1996;  37 81-86
    PubMedGoogle Scholar
  • 47 Jokeit H, Kramer G, Ebner A. Do antiepileptic drugs accelerate forgetting?.  Epilepsy Behav. 2005;  6 430-432
    CrossrefPubMedGoogle Scholar
  • 48 Yaari Y, Selzer M E, Pincus J H. Phenytoin: mechanisms of its anticonvulsant action.  Ann Neurol. 1986;  20 171-184
    CrossrefPubMedGoogle Scholar
  • 49 Gallassi R, Morreale A, Lorusso S. et al . Cognitive effects of phenytoin during monotherapy and after withdrawal.  Acta Neurol Scand. 1987;  75 258-261
    CrossrefPubMedGoogle Scholar
  • 50 Gallassi R, Morreale A, Lorusso S. et al . Carbamazepine and phenytoin. Comparison of cognitive effects in epileptic patients during monotherapy and withdrawal.  Arch Neurol. 1988;  45 892-894
    PubMedGoogle Scholar
  • 51 Pulliainen V, Jokelainen M. Comparing the cognitive effects of phenytoin and carbamazepine in long-term monotherapy: a two-year follow-up.  Epilepsia. 1995;  36 1195-1202
    CrossrefPubMedGoogle Scholar
  • 52 Duncan J S, Shorvon S D, Trimble M R. Effects of removal of phenytoin, carbamazepine, and valproate on cognitive function.  Epilepsia. 1990;  31 584-591
    PubMedGoogle Scholar
  • 53 Brown E S, Stuard G, Liggin J D. et al . Effect of phenytoin on mood and declarative memory during prescription corticosteroid therapy.  Biol Psychiatry. 2005;  57 543-548
    CrossrefPubMedGoogle Scholar
  • 54 Craig I, Tallis R. Impact of valproate and phenytoin on cognitive function in elderly patients: results of a single-blind randomized comparative study.  Epilepsia. 1994;  35 381-390
    CrossrefPubMedGoogle Scholar
  • 55 Beenen L F, Lindeboom J, Kasteleijn-Nolst Trenite D G. et al . Comparative double blind clinical trial of phenytoin and sodium valproate as anticonvulsant prophylaxis after craniotomy: efficacy, tolerability, and cognitive effects.  J Neurol Neurosurg Psychiatry. 1999;  67 474-480
    CrossrefPubMedGoogle Scholar
  • 56 Aldenkamp A P, Alpherts W C, Diepman L. et al . Cognitive side-effects of phenytoin compared with carbamazepine in patients with localization-related epilepsy.  Epilepsy Res. 1994;  19 37-43
    CrossrefPubMedGoogle Scholar
  • 57 Aldenkamp A P, Alpherts W C, Blennow G. et al . Withdrawal of antiepileptic medication in children – effects on cognitive function: The Multicenter Holmfrid Study.  Neurology. 1993;  43 41-50
    PubMedGoogle Scholar
  • 58 Pulliainen V, Jokelainen M. Effects of phenytoin and carbamazepine on cognitive functions in newly diagnosed epileptic patients.  Acta Neurol Scand. 1994;  89 81-86
    CrossrefPubMedGoogle Scholar
  • 59 Dodrill C B, Troupin A S. Neuropsychological effects of carbamazepine and phenytoin: a reanalysis.  Neurology. 1991;  41 141-143
    PubMedGoogle Scholar
  • 60 Dodrill C B, Temkin N R. Motor speed is a contaminating factor in evaluating the „cognitive” effects of phenytoin.  Epilepsia. 1989;  30 453-457
    CrossrefPubMedGoogle Scholar
  • 61 Taylor C P, Angelotti T, Fauman E. Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery.  Epilepsy Res. 2007;  73 137-150
    CrossrefPubMedGoogle Scholar
  • 62 Hindmarch I, Trick L, Ridout F. A double-blind, placebo- and positive-internal-controlled (alprazolam) investigation of the cognitive and psychomotor profile of pregabalin in healthy volunteers.  Psychopharmacology (Berl). 2005;  183 133-143
    CrossrefPubMedGoogle Scholar
  • 63 Macdonald R L, Kelly K M. Antiepileptic drug mechanisms of action.  Epilepsia. 1995;  36 (Suppl. 2) S2-12
    PubMedGoogle Scholar
  • 64 White H S. Molecular pharmacology of topiramate: managing seizures and preventing migraine.  Headache. 2005;  45 (Suppl. 1) S48-56
    CrossrefPubMedGoogle Scholar
  • 65 Fritz N, Glogau S, Hoffmann J. et al . Efficacy and cognitive side effects of tiagabine and topiramate in patients with epilepsy.  Epilepsy Behav. 2005;  6 373-381
    CrossrefPubMedGoogle Scholar
  • 66 Lee H W, Jung D K, Suh C K. et al . Cognitive effects of low-dose topiramate monotherapy in epilepsy patients: A 1-year follow-up.  Epilepsy Behav. 2006;  8 736-741
    CrossrefPubMedGoogle Scholar
  • 67 Romigi A, Cervellino A, Marciani M G. et al . Cognitive and psychiatric effects of topiramate monotherapy in migraine treatment: an open study.  Eur J Neurol. 2008;  15 190-195
    PubMedGoogle Scholar
  • 68 Aldenkamp A P, Baker G, Mulder O G. et al . A multicenter, randomized clinical study to evaluate the effect on cognitive function of topiramate compared with valproate as add-on therapy to carbamazepine in patients with partial-onset seizures.  Epilepsia. 2000;  41 1167-1178
    CrossrefPubMedGoogle Scholar
  • 69 de Araujo Filho G M, Pascalicchio T F, Lin K. et al . Neuropsychiatric profiles of patients with juvenile myoclonic epilepsy treated with valproate or topiramate.  Epilepsy Behav. 2006;  8 606-609
    CrossrefPubMedGoogle Scholar
  • 70 Kockelmann E, Elger C E, Helmstaedter C. Significant improvement in frontal lobe associated neuropsychological functions after withdrawal of topiramate in epilepsy patients.  Epilepsy Res. 2003;  54 171-178
    CrossrefPubMedGoogle Scholar
  • 71 Kockelmann E, Elger C E, Helmstaedter C. Cognitive profile of topiramate as compared with lamotrigine in epilepsy patients on antiepileptic drug polytherapy: relationships to blood serum levels and comedication.  Epilepsy Behav. 2004;  5 716-721
    CrossrefPubMedGoogle Scholar
  • 72 Martin R, Kuzniecky R, Ho S. et al . Cognitive effects of topiramate, gabapentin, and lamotrigine in healthy young adults.  Neurology. 1999;  52 321-327
    CrossrefPubMedGoogle Scholar
  • 73 Meador K J, Loring D W, Hulihan J F. et al . Differential cognitive and behavioral effects of topiramate and valproate.  Neurology. 2003;  60 1483-1488
    CrossrefPubMedGoogle Scholar
  • 74 Rosenberg G. The mechanisms of action of valproate in neuropsychiatric disorders: can we see the forest for the trees?.  Cell Mol Life Sci. 2007;  64 2090-2103
    CrossrefPubMedGoogle Scholar
  • 75 Thompson P J, Trimble M R. Sodium valproate and cognitive functioning in normal volunteers.  Br J Clin Pharmacol. 1981;  12 819-824
    CrossrefPubMedGoogle Scholar
  • 76 Gallassi R, Morreale A, Lorusso S. et al . Cognitive effects of valproate.  Epilepsy Res. 1990;  5 160-164
    CrossrefPubMedGoogle Scholar
  • 77 Dikmen S S, Machamer J E, Winn H R. et al . Neuropsychological effects of valproate in traumatic brain injury: a randomized trial.  Neurology. 2000;  54 895-902
    CrossrefPubMedGoogle Scholar
  • 78 Senturk V, Goker C, Bilgic A. et al . Impaired verbal memory and otherwise spared cognition in remitted bipolar patients on monotherapy with lithium or valproate.  Bipolar Disord. 2007;  9 (Suppl. 1) 136-144
    CrossrefPubMedGoogle Scholar
  • 79 Helmstaedter C, Wagner G, Elger C E. Differential effects of first antiepileptic drug application on cognition in lesional and non-lesional patients with epilepsy.  Seizure. 1993;  2 125-130
    CrossrefPubMedGoogle Scholar
  • 80 Siren A, Kylliainen A, Tenhunen M. et al . Beneficial effects of antiepileptic medication on absence seizures and cognitive functioning in children.  Epilepsy Behav. 2007;  11 85-91
    CrossrefPubMedGoogle Scholar
  • 81 Wilensky A J, Friel P N, Ojemann L M. et al . Zonisamide in epilepsy: a pilot study.  Epilepsia. 1985;  26 212-220
    CrossrefPubMedGoogle Scholar
  • 82 Berent S, Sackellares J C, Giordani B. et al . Zonisamide (CI-912) and cognition: results from preliminary study.  Epilepsia. 1987;  28 61-67
    CrossrefPubMedGoogle Scholar
  • 83 Ojemann L M, Ojemann G A, Dodrill C B. et al . Language Disturbances as Side Effects of Topiramate and Zonisamide Therapy.  Epilepsy Behav. 2001;  2 579-584
    CrossrefPubMedGoogle Scholar
  • 84 Park S P, Hwang Y H, Lee H W. et al . Long-term cognitive and mood effects of zonisamide monotherapy in epilepsy patients.  Epilepsy Behav. 2008;  12 102-108
    CrossrefPubMedGoogle Scholar
  • 85 Ketter T A, Post R M, Theodore W H. Positive and negative psychiatric effects of antiepileptic drugs in patients with seizure disorders.  Neurology. 1999;  53 S53-67
    PubMedGoogle Scholar
  • 86 Cochrane H C, Marson A G, Baker G A. et al . Neuropsychological outcomes in randomized controlled trials of antiepileptic drugs: a systematic review of methodology and reporting standards.  Epilepsia. 1998;  39 1088-1097
    CrossrefPubMedGoogle Scholar

PD Dr. Hennric Jokeit

Schweizerisches Epilepsie-Zentrum

Bleulerstr. 60

8008 Zürich, Schweiz

Email: h.jokeit@swissepi.ch

      >